Does the media refer more to CORT or ANVS?

In the previous week, Corcept Therapeutics had 45 more articles in the media than Annovis Bio. MarketBeat recorded 46 mentions for Corcept Therapeutics and 1 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.34 beat Corcept Therapeutics' score of 0.49 indicating that Annovis Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 15 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Annovis Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RPRX or CORT?

In the previous week, Corcept Therapeutics had 27 more articles in the media than Royalty Pharma. MarketBeat recorded 46 mentions for Corcept Therapeutics and 19 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.33 beat Corcept Therapeutics' score of 0.49 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 15 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 15 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ZTS or CORT?

In the previous week, Corcept Therapeutics had 14 more articles in the media than Zoetis. MarketBeat recorded 46 mentions for Corcept Therapeutics and 32 mentions for Zoetis. Zoetis' average media sentiment score of 1.42 beat Corcept Therapeutics' score of 0.49 indicating that Zoetis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 28 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 15 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CORT or JAZZ?

In the previous week, Corcept Therapeutics had 28 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 46 mentions for Corcept Therapeutics and 18 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.31 beat Corcept Therapeutics' score of 0.49 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 15 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Jazz Pharmaceuticals 15 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SUPN or CORT?

In the previous week, Corcept Therapeutics had 24 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 46 mentions for Corcept Therapeutics and 22 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.21 beat Corcept Therapeutics' score of 0.49 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 15 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Corcept Therapeutics (CORT) Competitors

$114.82 +0.34 (+0.29%)

As of 12:45 PM Eastern

Compare

CORT vs. ANVS, RPRX, ZTS, JAZZ, and SUPN

Should you buy Corcept Therapeutics stock or one of its competitors? MarketBeat compares Corcept Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corcept Therapeutics include Annovis Bio (ANVS), Royalty Pharma (RPRX), Zoetis (ZTS), Jazz Pharmaceuticals (JAZZ), and Supernus Pharmaceuticals (SUPN).

How does Corcept Therapeutics compare to Annovis Bio?

Corcept Therapeutics (NASDAQ:CORT) and Annovis Bio (NYSE:ANVS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Corcept Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	16.29	$99.65M	$0.42	273.19
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

Corcept Therapeutics has a net margin of 6.52% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Annovis Bio	N/A	-318.08%	-215.47%

In the previous week, Corcept Therapeutics had 45 more articles in the media than Annovis Bio. MarketBeat recorded 46 mentions for Corcept Therapeutics and 1 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.34 beat Corcept Therapeutics' score of 0.49 indicating that Annovis Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	15 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annovis Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics presently has a consensus price target of $119.17, suggesting a potential upside of 3.86%. Annovis Bio has a consensus price target of $11.67, suggesting a potential upside of 568.58%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Corcept Therapeutics beats Annovis Bio on 11 of the 15 factors compared between the two stocks.

How does Corcept Therapeutics compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Corcept Therapeutics (NASDAQ:CORT) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.44B	13.51	$770.95M	$1.47	38.95
Corcept Therapeutics	$761.41M	16.29	$99.65M	$0.42	273.19

54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Royalty Pharma has a net margin of 33.88% compared to Corcept Therapeutics' net margin of 6.52%. Royalty Pharma's return on equity of 29.25% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	33.88%	29.25%	14.71%
Corcept Therapeutics	6.52%	8.26%	6.45%

In the previous week, Corcept Therapeutics had 27 more articles in the media than Royalty Pharma. MarketBeat recorded 46 mentions for Corcept Therapeutics and 19 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.33 beat Corcept Therapeutics' score of 0.49 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	15 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	15 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Royalty Pharma has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

Royalty Pharma presently has a consensus target price of $56.57, suggesting a potential downside of 1.20%. Corcept Therapeutics has a consensus target price of $119.17, suggesting a potential upside of 3.86%. Given Corcept Therapeutics' higher possible upside, analysts clearly believe Corcept Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Summary

Royalty Pharma beats Corcept Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to Zoetis?

Zoetis (NYSE:ZTS) and Corcept Therapeutics (NASDAQ:CORT) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

In the previous week, Corcept Therapeutics had 14 more articles in the media than Zoetis. MarketBeat recorded 46 mentions for Corcept Therapeutics and 32 mentions for Zoetis. Zoetis' average media sentiment score of 1.42 beat Corcept Therapeutics' score of 0.49 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	28 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	15 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zoetis has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zoetis presently has a consensus target price of $118.33, indicating a potential upside of 52.53%. Corcept Therapeutics has a consensus target price of $119.17, indicating a potential upside of 3.86%. Given Zoetis' higher possible upside, equities analysts clearly believe Zoetis is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Zoetis has higher revenue and earnings than Corcept Therapeutics. Zoetis is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.53B	3.41	$2.67B	$6.03	12.87
Corcept Therapeutics	$761.41M	16.29	$99.65M	$0.42	273.19

Zoetis has a net margin of 27.80% compared to Corcept Therapeutics' net margin of 6.52%. Zoetis' return on equity of 66.85% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.80%	66.85%	18.79%
Corcept Therapeutics	6.52%	8.26%	6.45%

Summary

Zoetis beats Corcept Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to Jazz Pharmaceuticals?

Corcept Therapeutics (NASDAQ:CORT) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Corcept Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Corcept Therapeutics currently has a consensus price target of $119.17, suggesting a potential upside of 3.86%. Jazz Pharmaceuticals has a consensus price target of $259.06, suggesting a potential upside of 3.20%. Given Corcept Therapeutics' higher possible upside, research analysts clearly believe Corcept Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.90

Corcept Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	16.29	$99.65M	$0.42	273.19
Jazz Pharmaceuticals	$4.27B	3.69	-$356.15M	-$0.02	N/A

Corcept Therapeutics has a net margin of 6.52% compared to Jazz Pharmaceuticals' net margin of 0.66%. Jazz Pharmaceuticals' return on equity of 14.56% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

In the previous week, Corcept Therapeutics had 28 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 46 mentions for Corcept Therapeutics and 18 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.31 beat Corcept Therapeutics' score of 0.49 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	15 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jazz Pharmaceuticals	15 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Corcept Therapeutics beats Jazz Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Corcept Therapeutics compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Supernus Pharmaceuticals has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

Corcept Therapeutics has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.88	-$38.55M	-$0.51	N/A
Corcept Therapeutics	$761.41M	16.29	$99.65M	$0.42	273.19

In the previous week, Corcept Therapeutics had 24 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 46 mentions for Corcept Therapeutics and 22 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.21 beat Corcept Therapeutics' score of 0.49 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	15 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corcept Therapeutics has a net margin of 6.52% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Corcept Therapeutics	6.52%	8.26%	6.45%

Supernus Pharmaceuticals currently has a consensus price target of $62.83, indicating a potential upside of 30.68%. Corcept Therapeutics has a consensus price target of $119.17, indicating a potential upside of 3.86%. Given Supernus Pharmaceuticals' higher possible upside, equities research analysts clearly believe Supernus Pharmaceuticals is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

93.6% of Corcept Therapeutics shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Corcept Therapeutics beats Supernus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Corcept Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CORT vs. The Competition

Export

Metric	Corcept Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.38B	$11.47B	$6.80B	$12.66B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	272.66	796.51	282.16	25.05
Price / Sales	16.29	748.56	576.18	79.91
Price / Cash	126.82	14.82	28.60	46.71
Price / Book	18.63	10.33	10.96	6.18
Net Income	$99.65M	$2.81B	$3.49B	$347.61M
7 Day Performance	25.92%	0.31%	0.45%	0.71%
1 Month Performance	27.19%	-3.67%	-4.26%	-3.75%
1 Year Performance	66.29%	156.56%	63.09%	20.17%

Corcept Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CORT Corcept Therapeutics	3.0628 of 5 stars	$114.74 +0.2%	$119.17 +3.9%	+65.9%	$12.38B	$761.41M	272.66	300	Earnings Report Analyst Upgrade Analyst Revision
ANVS Annovis Bio	3.4699 of 5 stars	$1.74 -0.4%	$11.67 +569.3%	-30.1%	$60.63M	N/A	N/A	3
RPRX Royalty Pharma	4.1269 of 5 stars	$58.72 +0.5%	$56.57 -3.7%	+57.5%	$33.64B	$2.38B	39.95	80	Positive News Upcoming Earnings
ZTS Zoetis	4.9516 of 5 stars	$74.17 -1.6%	$119.50 +61.1%	-47.5%	$31.59B	$9.47B	12.30	14,500	Positive News Upcoming Earnings Gap Up
JAZZ Jazz Pharmaceuticals	2.5852 of 5 stars	$250.41 -1.5%	$259.06 +3.5%	+118.9%	$15.97B	$4.27B	N/A	2,890	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CORT) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corcept Therapeutics (CORT) Competitors

CORT vs. ANVS, RPRX, ZTS, JAZZ, and SUPN

How does Corcept Therapeutics compare to Annovis Bio?

Summary

How does Corcept Therapeutics compare to Royalty Pharma?

Summary

How does Corcept Therapeutics compare to Zoetis?

Summary

How does Corcept Therapeutics compare to Jazz Pharmaceuticals?

Summary

How does Corcept Therapeutics compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT vs. The Competition

Corcept Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corcept Therapeutics (CORT) Competitors

CORT vs. ANVS, RPRX, ZTS, JAZZ, and SUPN

How does Corcept Therapeutics compare to Annovis Bio?

Do institutionals and insiders hold more shares of CORT or ANVS?

Which has more risk & volatility, CORT or ANVS?

Which has better valuation and earnings, CORT or ANVS?

Is CORT or ANVS more profitable?

Does the media refer more to CORT or ANVS?

Do analysts recommend CORT or ANVS?

Summary

How does Corcept Therapeutics compare to Royalty Pharma?

Which has stronger valuation and earnings, RPRX or CORT?

Do institutionals & insiders have more ownership in RPRX or CORT?

Is RPRX or CORT more profitable?

Does the media favor RPRX or CORT?

Which has more risk and volatility, RPRX or CORT?

Do analysts recommend RPRX or CORT?

Summary

How does Corcept Therapeutics compare to Zoetis?

Does the media favor ZTS or CORT?

Which has more risk and volatility, ZTS or CORT?

Do institutionals and insiders hold more shares of ZTS or CORT?

Do analysts rate ZTS or CORT?

Which has better earnings & valuation, ZTS or CORT?

Is ZTS or CORT more profitable?

Summary

How does Corcept Therapeutics compare to Jazz Pharmaceuticals?

Which has more risk and volatility, CORT or JAZZ?

Do analysts prefer CORT or JAZZ?

Which has preferable earnings and valuation, CORT or JAZZ?

Is CORT or JAZZ more profitable?

Does the media refer more to CORT or JAZZ?

Do insiders & institutionals have more ownership in CORT or JAZZ?

Summary

How does Corcept Therapeutics compare to Supernus Pharmaceuticals?

Which has more risk & volatility, SUPN or CORT?

Which has preferable valuation and earnings, SUPN or CORT?

Does the media prefer SUPN or CORT?

Is SUPN or CORT more profitable?

Do analysts prefer SUPN or CORT?

Do institutionals and insiders have more ownership in SUPN or CORT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT vs. The Competition

Corcept Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools